Gastroesophageal reflux disease

Gastroesophageal reflux disease (GERD) is a common chronic, relapsing condition that is associated with a risk of significant morbidity and the possibility of mortality from complications. An estimated 44 percent of the U.S. adult population (61 million Americans) have heartburn, the hallmark of acid regurgitation, at least once a month. (1) Approximately 14 percent of Americans have gastroesophageal symptoms weekly, and 7 percent have symptoms daily. (1,2)

Many patients self-diagnose and self-treat, and do not seek medical attention for their symptoms, while others have more severe disease, including erosive esophagitis. (3) Patients who have GERD generally report decreased quality of life, reduced productivity, and decreased well-being. In many of these patients, reported quality of life is lower than in patients who have untreated angina pectoris or chronic heart failure. (4) This article summarizes an evidence-based approach to the cost-effective management of patients with GERD. (5)

Diagnosis

A careful history is essential to establish the diagnosis of GERD. If a patient has classic symptoms of heartburn and acid regurgitation, the diagnosis can be made with high specificity, yet the sensitivity remains low. (6,7) GERD can be missed in patients with heartburn, and some patients with Barrett's esophagus or adenocarcinoma of the esophagus do not complain of heartburn. Only 2 to 3 percent of acid reflux events reach the conscious level and are perceived by patients with GERD. (8) Furthermore, many patients with GERD present with atypical symptoms (6,7) (Table 1), (9) although the presence of such symptoms is not required for clinical diagnosis.

There is no gold standard for diagnosing GERD, although 24-hour pH monitoring (pH probe) is the accepted standard for establishing or excluding its presence. In patients with nonerosive reflux disease or symptomatic reflux esophagitis, 24-hour pH monitoring has a sensitivity and specificity of 70 to 96 percent, but false-positive or false-negative results are possible. (10) While endoscopy lacks sensitivity for identifying pathologic reflux, it is the gold standard for assessing esophageal complications of GERD. (11) Barium radiology is seldom useful for diagnosing GERD. (12)

In practice, the initial diagnosis of GERD is based on the history. Empiric acid suppression therapy for four to eight weeks should be tried in patients who have typical GERD symptoms without atypical manifestations and without warning signs or symptoms suggestive of complicated disease (13,14) (Table 2). (14) [Reference 13-evidence level A, meta-analysis of randomized controlled trials (RCTs)]

For the empiric trial, treatment may be initiated with a standard dosage of a histamine [H.sub.2]-receptor antagonist (H2RA) taken twice daily on demand or a standard dosage of a proton pump inhibitor (PPI) taken 30 to 60 minutes before the first meal of the day. The preferred empiric approach is step-up or step-down therapy. Step-up therapy begins with an eight-week trial of an H2RA and progresses to use of a PPI if symptoms of heartburn and regurgitation are not relieved. Step-down therapy starts with a PPI for eight weeks; treatment is then "downgraded" to the lowest effective dosage and type of medication that provide symptom relief. (15)

Drug selection should be based on the frequency or severity of symptoms at presentation, with a treatment goal of complete, cost-effective symptom relief (13,14) (Figure 1 (14) and Table 3 (5)). Diagnostic testing should be reserved for patients who present with warning signs and symptoms, have not responded to PPI therapy, or have disease duration of five to 10 years.

[FIGURE 1 OMITTED]

Treatment

LIFESTYLE MODIFICATIONS

Based on expert opinion, lifestyle modifications should be initiated and continued throughout the course of therapy in patients with a history that is typical of uncomplicated GERD (Table 4). (14) Although there is little supporting evidence, it is considered reasonable to educate patients about various factors that may precipitate reflux. (16)

ANTACIDS

Over-the-counter acid suppressants and antacids are considered appropriate initial therapy for GERD. Almost one third of patients with heartburn-related symptoms use one of these agents at least twice weekly, for an annual expenditure of more than $1 billion. (17,18) Antacids (e.g., Tums, Rolaids, Maalox) and combined antacid--alginic acid preparations have been shown to be more effective than placebo in relieving GERD symptoms, based on measures such as lower global symptom scores, less acid regurgitation, and fewer days and nights with heartburn. (19,20)

Sucralfate (Carafate), a prescription drug, increases the barrier to acid penetration in the esophagus. However, clinical studies have shown limited or no clinical efficacy for this agent in patients with GERD. (14)

HISTAMINE [H.sub.2]-RECEPTOR ANTAGONISTS

A number of RCTs have shown that H2RAs, given in standard dosages, are more effective than placebo for relieving heartburn in patients with GERD; within a few weeks of initiating treatment, up to 70 percent of patients reported symptomatic relief. (13,14) No RCTs or systematic reviews have compared recurrence rates of esophagitis symptoms in patients treated with H2RAs or placebo.

A systematic review of 43 RCTs found faster healing rates in patients with erosive esophagitis who were treated with H2RAs compared with placebo. (21) [Evidence level A, meta-analysis of RCTs] Higher dosages and more frequent dosing appear to increase the effectiveness of these agents in treating reflux symptoms and healing esophagitis. (22) Disadvantages of using maximal dosages of H2RAs may include cost (possibly equal to or higher than the cost of PPI therapy) and poor compliance with the medication regimen.

The U.S. Food and Drug Administration has approved the use of cimetidine (Tagamet), famotidine (Pepcid), nizatidine (Axid), and ranitidine (Zantac) as over-the-counter preparations, with the dosage for each medication uniformly one half of the standard lowest prescription dosage. The four agents have similar clinical efficacy.

Some patients with GERD may be able to predict when they will have reflux symptoms. These patients may benefit from premedication with an over-the-counter H2RA. Alternatively, patients may elect to take the medication when symptoms occur (on-demand therapy). The over-the-counter H2RAs are believed to be more effective than antacids, alginic acid, and placebo. (14)

The efficacy of promotility agents is similar to that of H2RAs when given in standard dosages. Promotility agents can be used to augment therapy; however, they are seldom used because of their association with rare fatal cardiac arrhythmias. (14)

The course of incompletely treated GERD has not been examined in randomized trials. Little information is available on the degree of gastric acid suppression that is necessary to ensure adequate esophageal healing. Patients may develop tolerance to H2RAs, with some decrease in efficacy occurring after 30 days of therapy.

Dosages of H2RAs may need to be decreased in the elderly and in patients with renal insufficiency. In some case reports, these agents have been associated with rare cytopenias, gynecomastia, liver function test abnormalities, and hypersensitivity reactions. No RCTs have examined the safety of long-term H2RA therapy.

PROTON PUMP INHIBITORS

If a patient who was initially started on twice-daily H2RA therapy does not respond after two weeks, appropriate step-up therapy is to switch to once-daily PPI therapy (Figure 1). (14) Evidence from several RCTs found that better control of reflux disease symptoms was achieved over a four- to eight-week period in patients treated with PPIs (83 percent) than in those given H2RAs (60 percent) or placebo (27 percent). (14) Evidence also indicates that step-up therapy and step-down therapy are cost-effective and should be used. (15,23) Furthermore, one study showed that a significantly greater number of patients treated with PPIs were in symptomatic remission at 12 months, compared with patients who were given H2RAs or placebo. (24) [Evidence level B, uncontrolled trial]

In the treatment of erosive esophagitis, faster healing rates were achieved in patients who received PPI therapy for four to eight weeks (78 percent) than in patients who were given H2RAs (50 percent) or placebo (24 percent) for the same period. (14) At one year, patients treated daily with a PPI were significantly less likely to relapse than those who received an H2RA. (25)

PPIs include lansoprazole (Prevacid), omeprazole (Prilosec), pantoprazole (Protonix), and rabeprazole (Aciphex). For these agents, no significant differences have been demonstrated in the symptomatic treatment of GERD or the healing of erosive esophagitis. Omeprazole recently became available in generic form, at only a slight reduction in cost compared with Prilosec. In the near future, an over-the-counter form of omeprazole should become available.

Esomeprazole (Nexium) is the S-isomer of omeprazole. Compared with omeprazole, esomeprazole is associated with higher rates of healing and symptom resolution in patients with GERD and reflux esophagitis. (26) [Evidence level B, uncontrolled trial]

In patients with chronic or complicated GERD, the potential benefit of long-term PPI therapy generally outweighs the risk of adverse events. The most common side effects include headache and diarrhea. Rarely, cobalamin absorption is decreased, but a clinically significant decrease in serum vitamin [B.sub.12] levels is unusual. The profound decrease in gastric acid secretion induced by PPIs leads to increased gastrin production from antral G cells. PPIs have not been linked to gastric cancer or carcinoid since their release more than 16 years ago. (27)

ANTIREFLUX SURGERY

Consideration of antireflux surgery must be individualized. Indications for surgery include failed medical management, patient preference for surgery despite successful medical management, complications of GERD, medical complications attributable to a large hiatal hernia, or atypical symptoms with reflux documented on 24-hour pH monitoring.

Potential surgical candidates should have reflux esophagitis documented by esophagogastroduodendoscopy and normal esophageal motility as evaluated by manometry. Patients being considered for surgery should have a defective antireflux barrier in the absence of poor gastric emptying. Potential candidates also should have at least a partial response to a previous trial of acid suppression therapy. The surgical referral should be made by a GERD subspecialist.

The basic tenets of surgery are the reduction of hiatal hernia, repair of diaphragmatic hiatus, strengthening of the gastroesophageal junction-posterior diaphragm attachment, and strengthening of the antireflux barrier through placement of a gastric wrap around the gastroesophageal junction (fundoplication). Surgery appears to be most effective for alleviating heartburn and regurgitation (beneficial in 75 to 90 percent of patients) and less effective for alleviating extraesophageal symptoms of cough, asthma, and laryngitis (beneficial in 50 to 75 percent of patients). (28)

While postsurgical complications are common, they are manageable in most patients. Approximately 10 percent of patients have solid food dysphagia; between 2 and 3 percent of these patients have permanent symptoms. From 7 to 10 percent of surgically treated patients have gas bloating; diarrhea, nausea, and early satiety occur more rarely. Although as many as 20 percent of patients have postsurgical complications, patient satisfaction is high when the symptoms of GERD are well controlled. (29)

Comparisons of antireflux surgery and antacid therapy in patients with erosive esophagitis have demonstrated marginal superiority for surgery as measured by heartburn relief, esophagitis healing, and improved quality of life. However, long-term follow-up studies have found that within three to five years of surgery, 52 percent of patients are taking antireflux medications again. (30)

NEWER ENDOSCOPIC TREATMENTS

The goals of radiofrequency heating of the gastroesophageal junction (Stretta procedure) and endoscopic gastroplasty (endocinch procedure) are to reduce medication use, improve quality of life, and decrease reflux symptoms in patients who have GERD, without the costs and risks associated with conventional antireflux surgery. Initial results for these treatments have been encouraging, with acid suppressant use decreased or eliminated in 50 to 75 percent of treated patients. (31)

To date, fewer than 10,000 patients have received any form of endoscopic antireflux treatment. Studies comparing postprocedure outcomes are currently in progress.

Follow-up

Further diagnostic testing should be performed in patients who have not responded to continuous therapy or who require such treatment, exhibit warning symptoms, or have risk factors for Barrett's esophagus. (14) Although chronic reflux plays a major role in the development of Barrett's esophagus, it is not known if outcomes can be improved through surveillance coupled with surgical or medical treatment. In observational studies, progression to severe esophagitis has not occurred in patients with an initial normal endoscopy whose symptoms have remained unchanged during 10-year follow-up, thus arguing against repeat endoscopy during that time period. (32)

The authors indicate that they do not have any conflict of interest. Sources of funding: Dr. Nostrant is a consultant and member of the speaker's bureau for AstraZeneca Pharmaceuticals LP, GlaxoSmithKline, Janssen Pharmaceutica Products, L.P., Merck & Co., Inc., TAP Pharmaceuticals Inc., and Wyeth Pharmaceuticals.

The authors thank all who assisted in the development and modification of the University of Michigan Health System (UMHS) guideline for the management of GERD, specifically those on the UMHS Guidelines Oversight Team.

REFERENCES

(1.) Sontag SJ. The medical management of reflux esophagitis. Role of antacids and acid inhibition. Gastroenterol Clin North Am 1990;19:683-712.

(2.) Hinder RA, Libbey JS, Gorecki P, Bammer T. Antireflux surgery. Indications, preoperative evaluation, and outcome. Gastroenterol Clin North Am 1999; 28:987-1005,viii.

(3.) Brunton S. Treatment strategies for patients with gastroesophageal reflux disease. Fam Pract Recertif 2002;24:51-64.

(4.) Dimenas E, Glise H, Hallerback B, Hernqvist H, Svedlund J, Wiklund I. Quality of life in patients with upper gastrointestinal symptoms. An improved evaluation of treatment regimens? Scand J Gastroenterol 1993;28:681-7.

(5.) University of Michigan Health System. Guidelines for clinical care. Management of gastroesophageal reflux disease (GERD). Retrieved May 28, 2003, from www.cme.med.umich.edu/pdf/guideline/gerd.pdf.

(6.) Klauser AG, Schindlbeck NE, Muller-Lissner SA. Symptoms in gastro-oesophageal reflux disease. Lancet 1990;335(8683):205-8.

(7.) Locke GR 3d, Talley NJ, Fett SL, Zinsmeister AR, Melton LJ 3d. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmstead County, Minnesota. Gastroenterology 1997;112:1448-56.

(8.) Richter JE, Bradley LC. Psychophysiological interactions in esophageal diseases. Semin Gastrointest Dis 1995;7:169-84.

(9.) Da Costa LR. Value of a therapeutic trial to diagnose gastroesophageal reflux disease: step up versus step down therapy. Can J Gastroenterol 1997; 11(suppl B):78B-81B.

(10.) Wiener GJ, Morgan TM, Copper JB, Wu WC, Castell DO, Sinclair JW, et al. Ambulatory 24-hour esophageal pH monitoring. Reproducibility and variability of pH parameters. Dig Dis Sci 1998; 33:1127-33.

(11.) Voutilainen M, Sipponen P, Mecklin JP, Juhola M, Farkkila M. Gastroesophageal reflux disease: prevalence, clinical, endoscopic and histopathological findings in 1,128 consecutive patients referred for endoscopy due to dyspeptic and reflux symptoms. Digestion 2000;61:6-13.

(12.) Johnston BT, Troshinsky MB, Castell JA, Castell DO. Comparison of barium radiology with esophageal pH monitoring in the diagnosis of gastroesophageal reflux disease. Am J Gastroenterol 1996;91: 1181-5.

(13.) Van Pinxteren B, Numans ME, Bonis PA, Lau J. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev 2001;(4):CD002095.

(14.) DeVault KR, Castell DO. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. The Practice Parameters Committee of the American College of Gastroenterology. Am J Gastroenterol 1999;94:1434-42.

(15.) Gerson LB, Robbins AS, Garber A, Hornberger J, Triadafilopoulos G. A cost-effectiveness analysis of prescribing strategies in the management of gastroesophageal reflux disease. Am J Gastroenterol 2000;95:395-407.

(16.) Meining A, Classen M. The role of diet and lifestyle measures in the pathogenesis and treatment of gastroesophageal reflux disease. Am J Gastroenterol 2000;95:2692-7.

(17.) Jones MP. Treating acid-related diseases: the current approach. Fam Pract Recertif 2000;22:71-84.

(18.) DeVault KR. Overview of medical therapy for gastroesophageal reflux disease. Gastroenterol Clin North Am 1999;28:831-45.

(19.) Weberg R, Berstad A. Symptomatic effect of a low-dose antacid regimen in reflux oesophagitis. Scand J Gastroenterol 1989;24:401-6.

(20.) Chatfield S. A comparison of the efficacy of the alginate preparation, Gaviscon Advance, with placebo in the treatment of gastro-oesophageal reflux disease. Curr Med Res Opin 1999;15:152-9.

(21.) Chiba N, De Gara CJ, Wilkinson JM, Hunt RH. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 1997;112:1798-810.

(22.) Simon TJ, Berlin RG, Tipping R, Glide L. Efficacy of twice daily doses of 40 or 20 milligrams famotidine or 150 milligrams ranitidine for treatment of patients with moderate to severe erosive esophagitis. Scand J Gastroenterol 1993;28:375-80.

(23.) Sridhar S, Huang J, O'Brien BJ, Hunt RH. Clinical economics review: cost-effectiveness of treatment alternatives for gastro-oesophageal reflux. Aliment Pharmacol Ther 1996;10:865-73.

(24.) Festen HP, Schenk E, Tan G, Snel P, Nelis F. Omeprazole versus high-dose ranitidine in mild gastroesophageal reflux disease: short- and long-term treatment. The Dutch Reflux Study Group. Am J Gastroenterol 1999;94:931-6.

(25.) Dent J, Yeomans ND, Mackinnon M, Reed W, Narielvala FM, Hetzel DJ, et al. Omeprazole v ranitidine for prevention of relapse in reflux oesophagitis. A controlled double blind trial of their efficacy and safety. Gut 1994;35:590-8.

(26.) Kahrilas PJ, Falk GW, Johnson DA, Schmitt C, Collins DW, Whipple J, et al. Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial. The Esomeprazole Study Investigators. Aliment Pharmacol Ther 2000;14:1249-58.

(27.) Klinkenberg-Knol EC, Nelis F, Dent J, Snel P, Mitchell B, Prichard P, et al. Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa. Gastroenterology 2000;118:661-9.

(28.) So JB, Zeitels SM, Rattner DW. Outcomes of atypical symptoms attributed to gastroesophageal reflux treated by laparoscopic fundoplication. Surgery 1998;124:28-32.

(29.) Spechler SJ, Lee E, Ahnen D, Goyal RK, Hirano I, Ramirez F, et al. Long-term outcome of medical and surgical therapies for gastroesophageal reflux disease: follow-up of a randomized controlled trial. JAMA 2001;285: 2331-8.

(30.) Lundell L, Miettinen P, Myrvold HE, Pedersen SA, Liedman B, Hatlebakk JG, et al. Continued (5-year) followup of a randomized clinical study comparing antireflux surgery and omeprazole in gastroesophageal reflux disease. J Am Coll Surg 2001;192:172-9.

(31.) Lehman GA. Endoscopic and endoluminal techniques for the control of gastroesophageal reflux: are they ready for widespread application? Gastrointest Endosc 2000;52:808-11.

(32.) Schnell TG, Sontag SJ, Chejfec G, Aranha G, Metz A, O'Connell S, et al. Long-term nonsurgical management of Barrett's esophagus with high-grade dysplasia. Gastroenterology 2001;120:1607-19.

JOEL J. HEIDELBAUGH, M.D., is clinical assistant professor in the Department of Family Medicine at the University of Michigan Medical School, Ann Arbor, and medical director of the Ypsilanti (Mich.) Health Center.

TIMOTHY T. NOSTRANT, M.D., is professor of internal medicine and physician director of the faculty diagnostic unit in the gastroenterology division at the University of Michigan Medical School.

CLARA KIM, M.D., is clinical instructor in the Department of Internal Medicine at the University of Michigan Medical School.

R. VAN HARRISON, PH.D., is associate professor in the Department of Medical Education and director of the Office of Continuing Medical Education at the University of Michigan Medical School.

Address correspondence to Joel J. Heidelbaugh, M.D., Ypsilanti Health Center, 200 Arnet, Suite 200, Ypsilanti, MI 48198 (email: jheidel@umich.edu). Reprints are not available from the authors.

COPYRIGHT 2003 American Academy of Family Physicians
COPYRIGHT 2003 Gale Group